Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07189299
NA

Microdosing LSD in Women With Premenstrual Disorders

Sponsor: Friederike Holze

View on ClinicalTrials.gov

Summary

The investigators aim to investigate the role of the serotonin 2A receptor in women with premenstrual disorders. This study uses a double-blind, randomized, controlled design with 3 arms: Intervention 1: 10 micg LSD for \~10 days during the late luteal phase (for 3 cycles) Intervention 2: 10 micg LSD every other day for \~10 days during the late luteal phase (for 3 cycles) Control intervention: Placebo for \~10 days during the late luteal phase (for 3 cycles) Each participant will be treated in only one arm. The study employs a parallel design with three treatment arms and consists of a two-cycle observational phase followed by a three-cycle treatment phase.

Official title: Role of the Serotonin 2A Receptor in Women With Premenstrual Disorders: a Randomized, Double-blind, Placebo-controlled Study (L4Her-Study)

Key Details

Gender

FEMALE

Age Range

18 Years - 45 Years

Study Type

INTERVENTIONAL

Enrollment

150

Start Date

2025-10-01

Completion Date

2030-01-01

Last Updated

2025-09-23

Healthy Volunteers

No

Conditions

Interventions

DRUG

LSD 10 μg every Day

Participants will receive 10 μg LSD every day during the luteal phase

DRUG

LSD 10 μg every other day

Participants receive 10μg LSD every second day during the luteal phase

DRUG

Placebo

Participants receive inactive placebo during the luteal phase

Locations (1)

Clinical Pharmacology & Toxicology, University Hospital Basel

Basel, Canton of Basel-City, Switzerland